TheraNatal Complete Recognized as Top Prenatal Vitamin by The Bump

July 8, 2024 6:00 AM

ROCKVILLE, MD / ACCESSWIRE / July 8, 2024 / Theralogix is proud to announce that TheraNatal® Complete has been featured in The Bump's latest article, "The Best Prenatal Vitamins, Tested by a Mom-to-Be." The article highlights TheraNatal Complete as the overall best prenatal, highlighting its exceptional formulation and multitude of benefits for expectant mothers. The Bump - from the creators of The Knot - is a premier online resource for expert...

Read more

Medical Physics Market Is Expected to Reach USD 10 Billion by 2034 And Grow at A CAGR of 6.4% | Future Market Insights, Inc.

July 8, 2024 4:10 AM

The medical physics market will certainly be forecasted at a valuation 10 billion with a CAGR of 6.4% by 2034, where the current market valuation is estimated to be USD 5.3 billion in 2024.Stringent radiation safety and equipment calibration regulations add complexity and costs to healthcare facilities, potentially hindering market growth. The scarcity of qualified medical physicists creates recruitment challenges and increases the workload on...

Read more

IRLAB: Invitation to the Interim Report for Q2 2024 Presentation and Webcast

July 8, 2024 1:20 AM

GOTHENBURG, SE / ACCESSWIRE / July 08, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, July 8, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that the company will hold a presentation in conjunction with the publication of the interim report for the period January-June 2024. The interim report will be published on...

Read more

StageZero Life Sciences Announces Update on Filing of Full Year 2023 Financials under the Failure to File Cease Trade Order

July 3, 2024 6:00 PM

StageZero Life Sciences, Ltd. (TSX:SZLS)(OTC PINK:SZLSF) ("StageZero" or the "Company"), an integrated healthcare company with the first and only mRNA gene expression multi-cancer diagnostic for screening for multiple, key cancers from a single sample of blood - Aristotle, and an oncologist-led adjunctive metabolic treatment protocol with early data - METRICS study - showing an improvement in outcome in cancer patients, today announced further...

Read more

Veterinarians Moonlight as Bartenders for a Cause

July 3, 2024 1:30 PM

VRCCO veterinarians serve beer at Ponch's Place for "Meet the Vet" nightsBEND, OR / ACCESSWIRE / July 3, 2024 / The veterinarians at the Veterinary Referral Center of Central Oregon have received advanced training in a range of different specialties, however, one particular subject may come as a surprise. A group of veterinarians recently completed a course to receive their Oregon alcohol servers permit in order to tend bar at Ponch's Place,...

Read more

Cosmos Health's Cana Laboratories Completes Facility Upgrades and Secures Contract Manufacturing Agreement with Provident Pharmaceuticals for 4.32 Million Vials of DE3-SOLE

July 3, 2024 1:05 PM

CHICAGO, IL / ACCESSWIRE / July 3, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its wholly-owned subsidiary, Cana Laboratories ("Cana"), has completed the...

Read more

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement

July 3, 2024 11:10 AM

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has entered into securities purchase agreements with health-care focused institutional investors for the purchase and sale of 1,425,000 shares of common stock in a registered direct offering and warrants to...

Read more

CHOWIS to Develop Customized Cosmetics Diagnostic Platform in Partnership With Kolmar Korea

July 3, 2024 8:15 AM

Chowis Co. Ltd. Skin, Hair and Scalp Solutions Provider Signs Agreement with Kolmar Korea to Develop AI driven Skin Analysis Platform.SEOUL, SOUTH KOREA / ACCESSWIRE / July 3, 2024 / Chowis Co. Ltd., a leading provider of AI skin diagnostic solutions in South Korea, has entered into a strategic partnership with Kolmar Korea to develop an advanced customized cosmetics diagnostic platform. Chowis - Kolmar Korea Chowis - Kolmar Korea On May 29th,...

Read more

Rose Villa Senior Living and The Malden Collective Partner to Launch the LiveWell(R) Tech Accelerator

July 3, 2024 8:00 AM

PORTLAND, OR / ACCESSWIRE / July 3, 2024 / Rose Villa Senior Living continues to drive innovation in senior living by partnering with The Malden Collective (TMC) to launch the LiveWell™ Tech Accelerator. Part of TMC's Innovation Hub, the Tech Accelerator gives emerging companies an opportunity to pilot proven technologies in a senior living environment. Rose Villa Senior Living Rose Villa Senior Living logo The first LiveWell™ Tech Accelerator...

Read more

Bioz Brings Cutting-Edge AI Citation Widgets to Precision X-Ray, Inc.'s Product Pages

July 3, 2024 4:00 AM

PALO ALTO, CA / ACCESSWIRE / July 3, 2024 / Bioz, Inc., a pioneering AI software company dedicated to enhancing scientific research, proudly announces its new partnership with Precision X-Ray, Inc. ("Precision"), a top provider of pre-clinical irradiation therapy and imaging systems. With thousands of citations validating the impact of Precision's cutting-edge technology, this collaboration aims to enhance research capabilities and drive...

Read more

iZafe Group Receives Confirmed Order of 500 Dosell Units from Ti Medi

July 3, 2024 3:20 AM

STOCKHOLM, SWEDEN / ACCESSWIRE / July 3, 2024 / iZafe Group (STO:IZAFE-B.ST) iZafe Group AB ("iZafe Group") today announces the receipt of an official order for 500 units of Dosell from Ti Medi, a dedicated partner of iZafe Group since April 2023. These units have recently been produced and will be delivered to Spain in August 2024, in time for Ti Medi's planned launch this fall of their new unique concept for the Spanish market.Ti Medi, in...

Read more

GSK and CureVac to Restructure Collaboration into New Licensing Agreement

July 3, 2024 2:40 AM

GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinationsCureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replacedLONDON, UK, TÜBINGEN, GERMANY and BOSTON, MA /...

Read more

CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities

July 3, 2024 2:40 AM

Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation to create leaner and more agile organizationPrioritization of high-value opportunities in oncology and other selected diseases, leveraging proprietary mRNA technology to develop novel treatment approachesCompany expects to deliver two or more clinical candidates by the end of 2025 and plans to initiate at least two...

Read more

MedMira Reports Third Quarter Results FY2024

July 2, 2024 11:00 PM

MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended April 30, 2024.Corporate updateIn Q3 FY2024, MedMira focused on the launch of MedMira's latest US FDA approved Reveal® G4 Rapid HIV 1/2 antibody test and continued its regulatory work in Canada and the United States. At the same time, the Company collaborated with a third party to complete MedMira's next commercial prototype for its patented MiROQ...

Read more

Cosmos Health Expands Collaboration with Papaellinas in Cyprus; Sky Premium Life Sales Expected to More Than Double to 150,000 Units Over Next 12 Months

July 2, 2024 3:30 PM

CHICAGO, IL / ACCESSWIRE / July 2, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has enhanced and expanded its strategic collaboration with C.A....

Read more

MD Clarity Named High Performer in G2’s Summer 2024 Report for RCM Software

July 2, 2024 9:42 AM

SEATTLE, WA / ACCESSWIRE / July 2, 2024 / MD Clarity today announced it has been named High Performer in G2's Summer 2024 Grid® Report. High Performers are earned based on receiving high customer satisfaction ratings compared to others in their category on G2, the world's largest software review marketplace.MDC horizontal logo Overall, MD Clarity earned a total of five accolades on G2, including:High PerformerBest SupportBest...

Read more

1933 Industries Reports Profit in Q3 2024 Financials

July 2, 2024 9:00 AM

1933 Industries Inc. (the "Company" or "1933 Industries") (CSE:TGIF)(OTCQB:TGIFF), a Nevada-focused cannabis cultivator and producer, is pleased to announce its unaudited interim consolidated financial statements for the three and nine months ended April 30, 2024 and 2023 ("Q3 2024"). All amounts expressed are in Canadian dollars.The Company owns 91% of Alternative Medicine Association (AMA), the Company's cultivation and production subsidiary...

Read more

Moderna Receives Project Award through BARDA's Rapid Response Partnership Vehicle Consortium to Accelerate Development of mRNA-based Pandemic Influenza Vaccine

July 2, 2024 7:30 AM

CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S....

Read more

Poolbeg Pharma PLC Announces Change of Registered Address

July 2, 2024 2:00 AM

Change of Registered AddressLONDON, UK / ACCESSWIRE / July 2, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), ('Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that the Company has changed its registered address to 40 Bank Street, Floor 24, London, E14 5NR, United Kingdom.EnquiriesPoolbeg Pharma Plc Jeremy...

Read more

IRLAB's Phase IIb Study of Pirepemat Can Proceed as Planned after Positive Opinion from External Safety Committee

July 2, 2024 1:20 AM

GOTHENBURG, SWEDEN / ACCESSWIRE / July 2, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, July 2, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that the independent Data Safety Monitoring Board (DSMB) has completed the last of two pre-determined safety and data integrity reviews of the ongoing Phase IIb study of...

Read more